VERTEX PHARMACEUTICALS INCVRTX

Market cap

$122.5B

P/E ratio

33.8x

	Dec 31, 2010	Dec 31, 2011	Dec 31, 2012	Dec 31, 2013	Dec 31, 2014	Dec 31, 2015	Dec 31, 2016	Dec 31, 2017	Dec 31, 2018	Dec 31, 2019	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023
Product	-	-	-	-	-	-	-	-	3,038	4,161	6,203	7,573	8,931	9,869
Other revenues	-	-	-	-	-	-	-	-	9	2	3	1	-	-
Revenue	143	1,411	1,527	1,212	580	1,032	1,702	2,489	3,048	4,163	6,206	7,574	8,931	9,869
Cost of sales	-	-	-	-	-	-	-	-	410	548	736	904	1,080	1,262
Research and development expenses	-	-	-	-	-	-	-	-	-	-	-	-	2,540	3,163
Research and Development in Process	-	-	-	-	-	-	-	160	-	-	-	-	116	-
Acquired in-process research and development expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	527
Selling, General and Administrative Expense	188	401	437	362	305	377	433	496	558	658	770	840	945	1,137
Change in fair value of contingent consideration	-	-	-	-	-	-	-	-	-	4	13	-3	-57	-52
Total costs and expenses	839	1,297	1,525	2,115	1,273	1,499	1,692	2,365	2,412	2,965	3,349	4,792	4,623	6,037
Income from operations	-696	114	2	-903	-692	-467	10	123	635	1,198	2,856	2,782	4,307	3,832
Interest income	-	-	-	-	-	-	-	-	-	64	22	5	145	615
Interest expense	-	-	-	-	-	-	-	-	-	-	-	-61	-55	-44
Other (expense) income, net	-	-	-	-50	30	-7	4	-81	-1	192	296	5	-165	-23
Income before provision for income taxes	-	60	-12	-976	-735	-558	-67	-16	600	1,395	3,117	2,730	4,232	4,380
Provision for income taxes	-	19	39	-289	7	30	17	-107	-1,487	218	405	388	910	760
Net income	-755	41	-51	-445	-739	-556	-84	263	2,097	1,177	2,712	2,342	3,322	3,620
Earnings Per Share, Basic	-3.77	0.14	-0.5	-1.98	-3.14	-2.31	-0.46	1.06	8.24	4.58	10.44	9.09	12.97	14.05
Earnings Per Share, Diluted	-3.77	0.14	-0.5	-1.98	-3.14	-2.31	-0.46	1.04	8.09	4.51	10.29	9.01	12.82	13.89